Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Indian Rupee: RBI seen on hold as growth solid – Commerzbank

Indian Rupee: RBI seen on hold as growth solid – Commerzbank

FXStreetFXStreet2026/07/30 08:24
By:FXStreet

Commerzbank’s analysts report that USD/INR has eased as India’s June industrial production surprised to the upside and inflation stayed within the Reserve Bank of India’s target band. Despite upside risks from commodities and monsoon-related pressures, the bank expects RBI to keep the repo rate unchanged in August, with INR gains limited by ongoing Dollar demand from Oil importers.

RBI cautious with INR supported

"June industrial production surprised to the upside, rising 7.4% yoy (Bloomberg consensus: 6.0%) vs 5.0% in May, marking the strongest reading since July 2024."

"However, forward-looking indicators suggest momentum could moderate in the coming months."

"Although inflation risks remain tilted to the upside due to higher global commodity prices and a weaker monsoon season, the latest report for June CPI showed it rose 4.4% yoy, which was within RBI's 2-6% target range."

"On monetary policy, the Reserve Bank of India (RBI) is expected to leave the benchmark repurchase rate unchanged at 5.25% at its next meeting on 5 August."

"In FX, USD/INR fell 0.2% to 95.64 yesterday, tracking the softer dollar. The pair eased back from the 96.80 level in the past week. RBI’s measures to attract inflows and limits on gold imports have provided some support for INR. However, further INR gains remain capped by USD demand from oil importers amid elevated global crude prices."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16